Despite prevailing financial market turbulence during the first quarter of 2015, it did not impede the ability of biotechs to raise capital. The period was characterized by a tsunami of cash flooding into their coffers. Both global public and private companies benefited from investors' seemingly insatiable appetite for their offerings. Read More

LONDON – Overall, the sums being raised may be smaller than in the U.S., but as the first quarter drew to a close the signs were that after re-opening their doors in 2014, capital markets are maintaining support for European biotech. Read More

"If the truth were known, mothers would really not want their children to be entrepreneurs," observed Hugh Young Rienhoff Jr., surmising that such a path – which he called part decision, part fate – suggested difficulties conforming to the corporate or academic worlds. Read More

The FDA is tweaking its plans to study how best to present price comparisons in physician and direct-to-consumer (DTC) ads without implying that two prescription drugs are interchangeable. While the research will focus on diabetes medications, the results could impact how drugmakers market biosimilars in the U.S. Read More

SHANGHAI – Increasingly, Chinese biotechs are finding the time is right to take their pipelines to the U.S., and Sihuan Pharmaceutical Holdings Group Ltd., China's fourth largest pharma company (in hospital sales), is the latest to take the leap. Read More

Bind Therapeutics Inc., of Cambridge, Mass., extended the terms of its global collaboration with New York-based Pfizer Inc. to create nanomedicines that optimize the therapeutic potential of two molecularly targeted cancer drugs in Pfizer's pipeline. Read More

Astellas Pharma Inc., of Tokyo, and the University of Texas MD Anderson Cancer Center in Houston, entered a collaboration to research and develop a new treatment for patients with acute myeloid leukemia that grants Astellas an option to firstly negotiate an exclusive, worldwide license at the end of phase Ib, with phase Ia and phase Ib studies to be conducted by MD Anderson. Read More

Collegium Pharmaceutical Inc., a Canton, Mass.-based company using its manufacturing platform Deterx to create an abuse-deterrent, extended-release, oral formulation of oxycodone now under review at the FDA, has filed to raise up to $86.3 million in an IPO. The company has yet to set terms for the offering. Read More

A team from the University of Iowa and the Chinese State Key Laboratory of Emerging Infectious Disease has gotten anti-MERS antibodies from where they are plentiful: camels. Read More